Showing results (61-70 of 101) with videos related to
Sort By:
Pageof 11
Cancer Chemotherapy and Pharmacology|January 1, 1987
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicityM P Goren, A A Forastiere, R K Wright, et al.Leukemia|February 1, 1990
Presenting features and treatment outcome of adolescents with acute lymphoblastic leukemiaV M Santana, R K Dodge, W M Crist, et al.International Journal of Radiation Oncology, Biology, Physics|April 2, 1993
Cumulative minutes with T90 greater than Tempindex is predictive of response of superficial malignancies to hyperthermia and radiationK A Leopold, M W Dewhirst, T V Samulski, et al.International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Relationships among tumor temperature, treatment time, and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomasK A Leopold, M Dewhirst, T Samulski, et al.Blood|October 1, 1985
Serum lactic dehydrogenase level has prognostic value in childhood acute lymphoblastic leukemiaC H Pui, R K Dodge, G V Dahl, et al.Gynecologic Oncology|March 31, 2000
The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinomaF D Cirisano, S J Robboy, R K Dodge, et al.Gynecologic Oncology|September 10, 1999
Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinomaF D Cirisano, S J Robboy, R K Dodge, et al.Leukemia|July 1, 1989
High serum interleukin-2 receptor levels correlate with a poor prognosis in children with Hodgkin's diseaseC H Pui, S H Ip, E Thompson, et al.Blood|January 1, 1989
Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcomeC H Pui, S H Ip, E Thompson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420E J Lee, S L George, M Caligiuri, et al.Pageof 11